Market analysts have apparently forecast huge growth in the market for biosimilars due to the upcoming loss of patent exclusivity for a number of branded drugs. Datamonitor has reportedly indicated that it expects the worldwide market for copies of biotech prescription drugs to grow from $243 million in 2010 to approximately $3.7 billion by 2015. The projections are based on the 30 branded biologics with sales exceeding $50 billion that will lose their patent protection between 2011 and 2015. Generic drugmakers have been moving into the biosimilars market; they have been joined by several global branded pharmaceutical companies. See Reuters, March 28, 2011.